Impact of levothyroxine therapy for maternal subclinical and overt hypothyroidism on early child neurodevelopment: A prospective cohort study
Clinical Endocrinology · 2024
DOI: 10.1111/cen.14984 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Zhekun Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Hypothyroidism, Pregnancy Complications. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai, National Key Research and Development Program of China, Science Foundation of Shanghai.
Abstract (Originalsprache)
Objective
Treatment indication of maternal subclinical hypothyroidism (SCH) is undetermined, despite the wide administration of levothyroxine for maternal overt hypothyroidism (OH). This study aimed to evaluate the therapeutic effect of levothyroxine for maternal SCH and OH in real‐world practice, with a focus on early child neurodevelopment.
Design
Prospective cohort study. Patients and Measurements Pregnant women diagnosed with SCH at the first antenatal visit were enroled and compared to those diagnosed with OH. Thyroid follow‐ups were conducted during pregnancy. Early child neurodevelopment was assessed using the Gesell Development Diagnosis Scale (GDDS) at 1, 3, 6, 12 and 24 months of age.
Results
From January 2012 to December 2013, a total of 442 pregnant women were included in final analysis, among whom 194 and 248 were assigned to the SCH and OH groups, respectively. The percentage of levothyroxine therapy at the first antenatal visit was significantly lower in the SCH group than that in the OH group (91.24% vs. 97.58%, p < .01), with a similar treatment rate at delivery (99.4% vs. 100%, p > .05). Notably, GDDS scores were lower in the SCH group than those in the OH group at 6 months to 2 years of age, which was confirmed by subgroup analyses and sensitivity analyses.
Conclusions
Children born with maternal SCH demonstrated slightly lower neuropsychological scores at 6 months to 2 years of age compared to those with maternal OH in the clinical practice. The therapeutic effect of maternal SCH on the child neurodevelopment requires further exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
- Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.
- Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China.
ORCID-Profile: Zhekun Zhao
Förderung
- Natural Science Foundation of Shanghai
- National Key Research and Development Program of China
- Science Foundation of Shanghai
- Shanghai Excellent Young Scholar Plan of Public Health
- Elite Young Scholar 2025 of Fudan University
- Shanghai Medical Center of Key Programs for Female Reproductive Diseases
- Shanghai Clinical Research Center for Gynecological Diseases
- Shanghai Urogenital System Diseases Research Center
Zitieren
APA
Zhao, Z., Zhao, H., Xiong, Y., Zhou, Q., & Li, X. (2024). Impact of levothyroxine therapy for maternal subclinical and overt hypothyroidism on early child neurodevelopment: A prospective cohort study. Clinical Endocrinology. https://doi.org/10.1111/cen.14984
Vancouver
Zhao Z, Zhao H, Xiong Y, Zhou Q, Li X. Impact of levothyroxine therapy for maternal subclinical and overt hypothyroidism on early child neurodevelopment: A prospective cohort study. Clinical Endocrinology. 2024. doi:10.1111/cen.14984
BibTeX
@article{Zhao2024,
author = {Zhao, Zhekun and Zhao, Huanqiang and Xiong, Yu and Zhou, Qiongjie and Li, Xiaotian},
title = {Impact of levothyroxine therapy for maternal subclinical and overt hypothyroidism on early child neurodevelopment: A prospective cohort study},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.14984}
}
EUVIMED